Exhibit 99.1

PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES ITS SECOND QUARTER FINANCIAL RESULTS

Pompano Beach, Florida, October 22, 2012 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended September 30, 2012.  Net income was $4.0 million, or $0.20 diluted per share, for the quarter ended September 30, 2012, compared to net income of $3.9 million, or $0.19 diluted per share, for the quarter ended September 30, 2011, a 6.0% increase to EPS.  Net income was $8.0 million, or $0.40 diluted per share, for the six months ended September 30, 2012, compared to net income of $8.8 million, or $0.41 diluted per share, for the six months ended September 30, 2011, a 4.0% decrease to EPS.  Net sales for the quarter ended September 30, 2012 were $58.1 million, compared to $58.2 million for the quarter ended September 30, 2011.  Net sales for the six months ended September 30, 2012 were $127.1 million, compared to $131.8 million for the six months ended September 30, 2011, a decrease of 3.6%.  Online sales increased 2.9% for the quarter ended September 30, 2012, with approximately 77% of all sales being generated via the Internet, compared to 74% for the same period the prior year.

Menderes Akdag, CEO and President, commented: “We were able to stabilize our top line and improve our bottom line results this quarter.  Net income growth in the quarter can be attributed to the leveraging of our operating expenses by saving 136 basis points.  The advertising costs of acquiring a new customer were reduced to $42 for the quarter ended September 30, 2012, compared to $43 for the same quarter the prior year.  Although sales were relatively flat during the quarter ended September 30, 2012, total orders increased by 5.5%, and reorder sales increased by 2.1%.  The unavailability of Novartis brands, due to the manufacturer’s suspended production, continued to negatively impact our sales.  During the quarter we repurchased 397,000 shares of our common stock for $3.9 million, at an average share price of $9.74.  Looking to the future, we will continue to focus on advertising efficiency and shifting sales to higher margin items, including generics, while continuing to expand our product offerings.”

This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter’s financial results.  To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (203) 827-7025.  Callers will be required to supply PETMEDS as the passcode.  For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. Eastern Time on October 22, 2012 until November 5, 2012 at 11:59 P.M. Eastern Time.  To access the replay, call (866) 407-9272 (toll free) or (203) 369-0617, and enter passcode 5500.

Founded in 1996, PetMed Express is America’s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.

This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan.  Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2012.  The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.

For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 954-979-5995.

###

Exhibit 99.1 Page 1 of 4

September 30,

March 31,

2012

2012

(Unaudited)

ASSETS

Current assets:

   Cash and cash equivalents

$

47,041

$

46,801

   Short term investments - available for sale

15,425

10,347

   Accounts receivable, less allowance for doubtful

      accounts of $6 and $5, respectively

1,888

1,572

   Inventories - finished goods

19,590

26,217

   Prepaid expenses and other current assets

1,047

1,241

   Deferred tax assets

852

1,230

   Prepaid income taxes

349

199

          Total current assets

86,192

87,607

   Property and equipment, net

2,311

2,597

   Intangible asset

860

860

Total assets

$

89,363

$

91,064

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

   Accounts payable

$

6,956

$

6,619

   Accrued expenses and other current liabilities

2,067

2,772

          Total current liabilities

9,023

9,391

Deferred tax liabilities

227

492

Total liabilities

9,250

9,883

Commitments and contingencies

Shareholders' equity:

   Preferred stock, $.001 par value, 5,000 shares authorized;

      3 convertible shares issued and outstanding with a

      liquidation preference of $4 per share

9

9

   Common stock, $.001 par value, 40,000 shares authorized;

      20,007 and 20,338 shares issued and outstanding, respectively

20

20

   Retained earnings

80,015

81,108

   Accumulated other comprehensive gain

69

44

          Total shareholders' equity

80,113

81,181

Total liabilities and shareholders' equity

$

89,363

$

91,064

Three Months Ended

Six Months Ended

September 30,

September 30,

2012

2011

2012

2011

 Sales

$

58,145

$

58,225

$

127,100

$

131,803

 Cost of sales

38,775

38,291

85,426

87,759

 Gross profit

19,370

19,934

41,674

44,044

 Operating expenses:

      General and administrative

5,371

5,604

11,293

11,708

      Advertising

7,424

7,904

17,274

18,004

      Depreciation

249

346

577

687

 Total operating expenses

13,044

13,854

29,144

30,399

 Income from operations

6,326

6,080

12,530

13,645

 Other income:

      Interest income, net

64

72

123

158

      Other, net

-

64

-

63

 Total other income

64

136

123

221

 Income before provision for income taxes

6,390

6,216

12,653

13,866

 Provision for income taxes

2,356

2,286

4,667

5,099

 Net income

$

4,034

$

3,930

$

7,986

$

8,767

 Net income per common share:

       Basic

$

0.20

$

0.19

$

0.40

$

0.41

       Diluted

$

0.20

$

0.19

$

0.40

$

0.41

Weighted average number of common shares outstanding:

       Basic

19,962

20,642

20,040

21,142

       Diluted

20,062

20,710

20,154

21,238

 Comprehensive income

$

4,050

$

3,979

$

8,011

$

8,909

 Cash dividends declared per common share

$

0.150

$

0.125

$

0.300

$

0.250

Six Months Ended

September 30,

2012

2011

 Cash flows from operating activities:

    Net income

$

7,986

$

8,767

    Adjustments to reconcile net income to net cash

     provided by operating activities:

        Depreciation

577

687

        Share based compensation

1,039

1,127

        Deferred income taxes

113

114

        Bad debt expense

27

25

        (Increase) decrease in operating assets

           and increase (decrease) in liabilities:

             Accounts receivable

(343

)

527

             Inventories - finished goods

6,627

6,026

             Prepaid income taxes

(150

)

(26

)

             Prepaid expenses and other current assets

194

(923

)

             Accounts payable

337

86

             Accrued expenses and other current liabilities

(673

)

(215

)

 Net cash provided by operating activities

15,734

16,195

 Cash flows from investing activities:

    Net change in investments

(5,053

)

9,693

    Purchases of property and equipment

(291

)

(293

)

 Net cash (used in) provided by investing activities

(5,344

)

9,400

 Cash flows from financing activities:

    Dividends paid

(6,117

)

(5,404

)

    Purchases of treasury stock

(3,865

)

(22,642

)

    Tax adjustment related to restricted stock

(168

)

(71

)

 Net cash used in financing activities

(10,150

)

(28,117

)

 Net increase (decrease) in cash and cash equivalents

240

(2,522

)

 Cash and cash equivalents, at beginning of period

46,801

49,660

 Cash and cash equivalents, at end of period

$

47,041

$

47,138

 Supplemental disclosure of cash flow information:

    Cash paid for income taxes

$

4,872

$

5,083

    Dividends payable in accrued expenses

$

136

$

135